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Abstract: This paper reviews recent advances and investigation in the treatment of ocular 
surface pathology. There is significant investment in this area, paralleling the growing demand 
for more effective alternatives to current treatments. Clinicians are becoming more aware of 
surface pathology, yet the ability to treat the most common forms of ocular pathology are still 
limited to the few medications approved by the US Food and Drug Administration. Medicines 
and devices currently under investigation are very promising. It is absolutely critical to understand 
the emerging options and think of their role in the treatment paradigm.
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Introduction
In the last 15 years, there has been significant research and interest in the area of ocular 
surface disease. The majority of this research has targeted decreasing ocular surface 
inflammation and promoting the healthy tear complex. The focus is on the underlying 
pathogenic pathways, and continues to be guided by careful study of the “immune tone” 
of the lacrimal apparatus tasked with protecting and nourishing the ocular surface. 
For example, understanding the cytokine and chemokine concentrations in patients 
without clinical pathology serves as a reference point for further study of patients 
suffering from ocular surface disease.1 The clinical significance of dysfunctional 
tear syndrome and ocular surface disease is of increasing importance to clinicians, 
as we continue to uncover pertinent coincident pathology. When compared with 
patients without dysfunctional tear syndrome, patients suffering from dysfunctional 
tear syndrome and ocular surface disease are more likely to have systemic disease, 
including ischemic heart disease, stroke, cardiac arrhythmias, collagen vascular disease 
(such as rheumatoid arthritis), and depression.2 Attention to these potential medical 
comorbidities is essential. Numerous studies have also demonstrated ocular surface 
disease and dysfunctional tear syndrome as increasingly impacting on key tasks of 
daily living, and have advocated that attention be paid to their implications as a public 
health problem.3
The renewed focus on the development of new treatments can be attributed to a 
better understanding of the etiology of tear complex breakdown and development of 
dysfunctional tear syndrome. Along with new data driving the interest in this area, the 
lack of medicines approved by the US Food and Drug Administration specifically for the 
treatment of dysfunctional tear syndrome drives companies to invest in the development 
of the next key molecule. RestasisTM (0.05% cyclosporine, Allergan, Irvine, CA) is Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the only medication currently approved by the Food and 
Drug Administration for the treatment of dysfunctional 
tear syndrome. New drugs using alternative mechanisms 
are being examined by several pharmaceutical companies. 
There is much to gain from the development of this next key 
medication. This is further driven by the fact that Restasis 
sales in 2008 yielded $444 million.4 Most of the material 
described in this paper is either still in investigation or off-
label application of available devices or medications.
Immunomodulators
Several pharmaceutical companies are investing in the 
development of a potentially more effective cyclosporine 
formulation. This is largely due to reports of the superior effi-
cacy of the 0.1% concentration when compared with 0.05%, 
suggesting that cyclosporine could be even more relevant in 
the treatment of dysfunctional tear syndrome. Restasis XTM 
(cyclosporine 0.1%) is under investigation in Phase II trials 
by Allergan.5 ZyclorinTM (cyclosporine 0.1%), is a topical 
ophthalmic immunomodulator and immunosuppressive 
agent under investigation which is building on the success 
of Restasis. Zyclorin differs from Restasis in that it contains 
double the concentration of cyclosporine. It is currently 
under Phase III clinical investigation by Alcon and Sirion 
Pharmaceuticals.6 CyclokatTM (cyclosporine 0.1%) uses a 
mechanism of immunomodulation similar to that of Restasis 
and   Zyclorin, and has also completed Phase III investigation. 
The key distinguishing feature of Cyclokat is the use of a 
proprietary cationic ophthalmic emulsion as a carrier. Due to 
the electrostatic attraction between the positively charged eye 
drop and the negatively charged ocular surface, Cationorm® 
claims to spread in a more optimal manner over the ocular 
surface with greater uniformity.7
LX-214 (voclosporin) belongs to a class of agents known 
as calcineurin phosphate inhibitors. Two   calcineurin phos-
phate inhibitors are commercially available in the US, 
ie, tacrolimus (ProtopicTM, Astellas, Tokyo, Japan), which is 
available as 0.03% and 0.1% ointments, and topical pimecroli-
mus (Elidel®, Novartis, Basel,   Switzerland), which is avail-
able as a 1% cream. Both tacrolimus and pimecrolimus act on 
T lymphocytes, which play a critical role in the   inflammatory 
cascade. The calcineurin phosphate inhibitors are complex 
compounds that bind to macrophilin-12, an intracellular 
protein. This complex inhibits the phosphorylase enzyme, 
calcineurin, which prevents translocation of the nuclear 
factor of activated T cells. The signaling pathway for nuclear 
factor of activated T cells targets specific genes in T cells, 
including interleukin (IL)-2, IL-3, IL-4, IL-10, interferon-γ, 
and granulocyte-macrophage colony-stimulating factor. 
Systemic administration of   tacrolimus (PrografTM,   Astellas) 
and cyclosporine is implicated in the development of lym-
phoma, particularly post-transplant lymphoproliferative 
disorder and nonmelanoma skin cancers.8 The basis of 
this increased risk for malignancy is related to sustained 
profound systemic   immunosuppression. The lymphomas 
that occur in this setting are usually B cell lymphomas, 
which develop weeks to months after therapy. Theoretical 
concerns that topical administration of calcineurin inhibitors 
could result in either lymphomas similar to post-transplant 
lymphoproliferative disorder or nonmelanoma skin cancers 
are based on the assumptions that enough systemic absorp-
tion could occur with the topical use of calcineurin phosphate 
inhibitors to promote the development of these malignancies. 
  Calcineurin phosphate inhibitors may inhibit DNA repair in 
epidermal keratinocytes, and prolonged use over many years 
could result in an increased risk of skin cancer.8 However, 
it is important to emphasize that knowledge of systemic 
calcineurin phosphate inhibitor-associated malignancies 
preceded the development and licensing of both tacrolimus 
and pimecrolimus in topical forms. Their approval as topi-
cal medications relied on large clinical trials demonstrating 
low to negligible blood levels, minimal to no evidence of 
systemic or cutaneous infections with topical use, and other 
safety parameters.
Lux Biosciences has reported LX-214 to be very well 
tolerated in a Phase I study, and there was no difference 
in tolerability between the vehicle control and the two 
concentrations tested, ie, 0.2% and 0.02%.9 These positive 
early tolerability results with the 0.2% formulation appear to 
have an advantage over the formulations discussed earlier.
Tasocitinib (CP-690, 550, Pfizer, New York, NY) is a drug 
which inhibits the Janus kinase (JAK)3 enzyme, found only 
in immune cells, and discovered in the course of examining 
severe combined immunodeficiency disease (also known as 
“bubble boy disease”). This condition results when muta-
tions occur in the genome responsible for creating the JAK3 
enzyme. Because cytokines play pivotal roles in immunity 
and inflammation, targeting of cytokines and their receptors 
represents an effective means of treating conditions with 
inflammation as their hallmark.10 JAKs are a small family of 
receptor-associated kinases that, together with signal trans-
ducers and activators of   transcription, provide a rapid signal-
ing pathway for cytokines. Four JAKs have been identified, 
ie, JAK1, JAK2, JAK3, and tyrosine kinase 2. JAK3 has 
attracted much attention as an anti-inflammatory drug target 
because of its restricted expression in hematopoietic tissue and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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because of its   specific association with the   common gamma 
chain of the IL-2 receptor, which is shared by the receptors 
for IL-4, IL-7, IL-9, IL-15, and IL-21.10 Pfizer has been 
very active in this field, with evaluation of JAK3 inhibition 
in a number of inflammatory diseases, including rheumatoid 
arthritis, asthma, ulcerative colitis, Crohn’s disease, psoriasis, 
and   prevention of transplant rejection.11 Results from the 
first Phase II study of Pfizer’s JAK3 inhibitor revealed 
the best reported results so far for a small molecule tested 
in rheumatoid arthritis. JAK2   gain-of-function mutations 
(JAK2V617F) trigger a subset of disorders collectively 
referred to as myeloproliferative disorders.11 Advanced 
JAK2 inhibitors are also being evaluated in Phase II 
  trials for   myelofibrosis,   polycythemia vera, and essential 
thrombocythemia. A Phase II study is currently enrolling 
280 patients.12
Tacrolimus (FK-506) is a potent immunosuppressive 
agent under investigation in Phase IIB studies for the treat-
ment of dysfunctional tear syndrome. Like Restasis, it also 
targets inflammatory mediators. Tacrolimus was discovered 
in 1984 and is used worldwide in patients receiving organ 
transplantation. It is also being used in the US as a topical 
eyelid ointment (Protopic 0.03%) for the treatment of atopic 
dermatitis. Although Protopic has been shown to be very 
effective as an eyelid ointment, it is not currently approved 
for ophthalmic use.13
Secretagogs
Mucin is a critical component of the healthy ocular 
surface. It is a glycoprotein that lubricates the epithelium 
while anchoring the tear film. Diquafosol tetrasodium 
2% (ProlacriaTM) is a mucin secretagog which has shown 
promising early results in the treatment of dysfunctional 
tear syndrome.14 Diquafosol is an internally developed P2Y2 
agonist targeting the Gq protein-coupled P2Y2 receptor, 
a member of the adenosine triphosphate receptor family, 
which triggers a series of events, resulting in nonglandular 
secretion of fluid (water transport via chloride channel 
activation), mucin secretion, and possibly lipid production 
in the meibomian glands. Purinergic receptors are found on 
three cell types, ie, goblet cells, ciliated epithelial cells, and 
Type II alveolar cells. Discovery of diquafosol stemmed 
from research into cystic fibrosis and chronic obstructive 
pulmonary diseasein the late 1990s.15
Phase III six-month results ofdiquafosol tetrasodium 1% 
and 2% have recently been reported.16 In this study, corneal 
and conjunctival staining in the diquafosol treatment groups 
was significantly lowered compared with placebo as early 
as two weeks following initiation of treatment. This benefit 
was maintained throughout the duration of the study. Of note, 
one week after cessation of therapy, the beneficial effects of 
treatment were diminished.
In 2007, Brazzell et al reported the results of the 
relevant US clinical trials at the annual meeting of the 
Association for Research in Vision and Ophthalmology.14 
This was a summary of seven US clinical trials in over 
2000 subjects for durations ranging from one day to one 
year. Four of these were Phase III studies (104, 105, 108, 
and 109). A variety of objective and subjective endpoints 
were evaluated in these trials, including fluorescein staining 
of the cornea, lissamine green staining of the conjunctiva, 
Schirmer’s test, tear breakup time, and subject-reported 
symptoms. Corneal fluorescein staining, total clearing 
of the ocular surface, and clearing of the central cornea 
were evaluated. In studies 105 and 109, subjects receiving 
diquafosol 2% demonstrated significantly (P # 0.001) 
lower mean corneal and conjunctival staining scores 
compared with subjects receiving placebo after six weeks 
of four times daily dosing. In study 105, administration of 
diquafosol resulted in a 75% increase in Schirmer scores 
compared with administration of placebo. Diquafosol has 
been shown in clinical trials to promote clearing of corneal 
staining.
In study 105, subjects treated with diquafosol were four 
times more likely to have a corneal staining score of zero 
following six weeks of treatment than were subjects treated 
with placebo. In study 108, subjects treated with diquafosol 
were three times more likely to have an ocular staining 
score of zero following four weeks of treatment than were 
subjects treated with placebo. In both of these studies, the 
differences in the proportion of patients with total clearing 
were statistically significant (P # 0.05). In studies 105 and 
109, subjects treated with diquafosol were significantly 
(P # 0.05) more likely to have zero staining in the central 
region of the cornea at their end-of-treatment clinic visit 
than were subjects treated with placebo. In study 108, this 
difference approached significance (P = 0.052). Importantly, 
in studies 104 and 105, a relationship between central corneal 
clearing status and signs and symptoms was noted. Subjects 
in these trials who had a clear central cornea following 
six weeks of treatment had significantly lower (P # 0.05) 
symptom scores than did subjects who did not have a clear 
central cornea at six weeks. Diquafosol appears to be one 
of the more promising new medications in ocular surface 
disease. A diquafosol 3% formulation (Diquas®) gained 
approval in Japan in April 2010.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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IB-MECA (CF101) is an oral treatment which also uses 
the common mechanistic pathways shared between purine 
receptor family members. Binding of CF101 to this adenosine 
receptor agonist initiates downstream signal transduction 
pathways, which, in turn, downregulate protein kinases, and 
inhibit production of tumor necrosis factor-α. In addition, 
CF101 inhibits the proliferation of autoreactive T cells and 
production of chemokines.17 Clinical investigators undertook 
a multicenter, randomized, double-masked, placebo-
  controlled, parallel-group study in 68 patients.17 Treatment 
with CF101 resulted in a statistically significant improvement 
in the mean change from baseline at week twelve for corneal 
staining, breakup time, and meniscus height. Interestingly, 
there was also a significant pressure-lowering effect in the 
treated group and, as such, there is significant interest in this 
medication for many reasons.
Rebamipide is an amino acid derivative of 2(1H)-
quinolinone which also stimulates mucus secretion. Studies 
have demonstrated that impaired generation of prostaglandins 
is evident in the gastric and duodenal mucosa of patients with 
peptic ulcers.18–21 Prostaglandin deficiency, in turn, impedes 
ulcer healing and increases the future risk of relapse.18 
Rebamipide is a mucoprotective agent widely used in the 
treatment of gastric ulcers, and stimulates mucus secretion by 
inducing prostaglandin E2 production. Rebamipide activates 
the EP-4 gene, downregulates neutrophil production, and 
scavenges free radicals.19 This agent is currently under 
Phase III investigation by Acucela Pharmaceuticals in 
partnership with the Otsuka Pharmaceutical Group. Data 
presented at the Association for Research in Vision and 
Ophthalmology annual meeting in 2010 reported 1% and 
2% concentrations of rebamipide to be more effective than 
placebo in treating dysfunctional tear syndrome.
Ecabet sodium is another medication targeting mucin 
secretion, and is currently being marketed in Japan as an 
oral agent for the treatment of gastric ulcers and ulcerative 
colitis. It is available in Japan as Gastrom®. It targets the 
prostaglandin E2 pathway, inhibiting pepsin formation 
and increasing blood flow. Ecabet sodium may also 
downregulate reactive oxygen species on the ocular surface, 
functioning similar to an anti-inflammatory agent.22 ISTA 
Pharmaceuticals Inc, is currently investigating ecabet sodium 
in Phase III trials being performed in a novel controlled 
adverse environment laboratory setting. This environment 
mimics environmentally-induced changes to the ocular 
surface. ISTA has reported trends for improvements in blink 
rate and Ocular Symptom Disease Index score (subjective 
assessment of patients’ most bother some symptom) in 
144 patients, with four times daily dosing, versus placebo, 
for 43 days.
Disaccharide protectants
Trehaloseis a naturally occurring disaccharide formed 
by bonding two glucose molecules together, imparting 
high water retention, and is synthesized by fungi, plants, 
and invertebrate animals. It is thought to form a gel as it 
dehydrates, which allows it to “splint” internal components 
of cells which would otherwise be damaged by desiccation. 
Trehalose has been found to have antioxidant properties as 
well as significant resistance to heat or acidic conditions.23 
Its molecule bonding properties keep glucose in a closed 
ring form which promotes better stability. It is prevalent in 
shrimps and insects, where blood sugar is found in this form. 
Several studies have demonstrated the healing properties 
of trehalose in the human corneal epithelium. Matusoet al 
performed an in vitro study with cultured human epithelial 
cells which effectively showed a reduction in cell death 
versus sodium hyaluronate, phosphate-buffered solution, 
and maltose.23 Trehalose has also demonstrated superiority 
over commercially available lubricants for moderate to 
severe dysfunctional tear syndrome patients in 36 patients 
during an eight-week crossover study in which sodium 
fluorescein tear breakup time and Rose Bengal staining 
were assessed.24
Nonsteroidal anti-inflammatory 
drugs
Nonsteroidal anti-inflammatory drugs have been used 
successfully to address the impact of inflammation on 
the ocular surface. Targeting the inflammation yields 
improvement in both subjective and objective signs of ocular 
surface disease. Using nonsteroidal anti-inflammatory drugs 
in the treatment of dysfunctional tear syndrome and ocular 
surface diseasehelps address pain, a key symptom which can 
be challenging to mitigate, especially given that at times it 
does not coincide with the clinical picture.
Low-dose bromfenac (RemuraTM) is under Phase II 
investigation by ISTA, and has demonstrated improvement 
in lissamine green and ocular surface disease scores in 
38 patients over a six-week period.25 A Phase III study 
was initiated in September 2010. Thirty sites in the US 
are investigating twice-daily dosing at concentrations of 
0.03% and 0.06% (both lower than XibromTM 0.09%). 
Nonsteroidal anti-inflammatory drugs have been implicated 
in corneal melt and decreased corneal sensitivity.26 A low-
dose nonsteroidal anti-inflammatory drug with a good safety Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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profile that yields clinical improvement would be a significant 
addition to the treatment of ocular surface disease. Another 
significant advantage of this class of agents is that the onset 
of action is faster than the typical six to eight week period that 
is sometimes necessary when using topical cyclosporine.
Corticosteroids
Decreasing inflammation of the ocular surface is a key step 
en route to restoring conjunctival and corneal epithelium 
compromised due to dysfunctional tear syndrome and various 
other inflammatory conditions such as blepharitis, allergy, 
and autoimmune disease. We often find it necessary to use 
steroid drops and ointments intermittently in response to 
acute disease. Typically the side effect profile with respect 
to cataract formation or steroid-induced glaucoma limits 
their chronic use.
EGP-437 is a dexamethasone-derived corticosteroid under 
investigation in a Phase III study by EyeGate Pharmaceuticals. 
The use of iontophoresis distinguishes this new treatment 
from other agents in development. EGP-437 is delivered to 
the ocular surface via an ocular applicator with a central foam 
reservoir saturated with the drug. This reservoir is placed 
in the perilimbal conjunctiva. An electrode is placed on the 
patient’s forehead and the ocular applicator is connected to 
a small, handheld, programmable generator. The generator 
supplies a negative charge to the ocular applicator and uses the 
resulting electrorepulsion to push the drug at a high velocity 
into the eye. This innovative iontophoretic drug delivery 
system allows the EGP-437 to be maximally absorbed 
into the ocular surface and overcomes the problem of low 
bioavailability. Other topical agents have been plagued by 
this problem. The ability to bypass barriers en route to the 
site of action is a significant advantage. Current attempts at 
applying medicines to the ocular surface have been difficult 
to implement clinically, and have not been efficient. Both 
the drug and the device are under Phase III investigation. 
Titrating the level and duration of current application dictates 
the quantity of drug which ultimately penetrates the ocular 
surface. According to EyeGate, the iontophoresis process 
takes only a couple of minutes. If the drug delivery system 
proves to be effective in the clinic, this could be a welcome 
new treatment with many applications, because any drug can 
be loaded into the applicator. This device may be especially 
useful in treatment of certain retinal conditions.
Lotoprednol etabonate 0.5% (LotemaxTM) has played an 
effective role in the treatment paradigm of ocular surface 
disease by controlling inflammation, with a lower ten-
dency to cause spikes in intraocular pressure and to induce 
cataract formation.27 The addition of Lotemax in an ointment 
form will allow for anti-inflammatory coverage at night 
before   bedtime, which may be better tolerated than currently 
available topical steroid preparations.
Omega-3 fatty acids
Studies have demonstrated the anti-inflammatory impact 
of orally administered essential fatty acids on the ocular 
  surface.28 The naturally occurring essential polyunsaturated 
fatty acids, omega-3 and omega-6, have been shown to have 
many positive effects on inflammatory diseases, including 
rheumatoid arthritis and ulcerative colitis. Alpha-linolenic 
acid has also been shown to improve the ocular surface when 
applied topically. Alpha-linolenic acid applied topically to 
dry eyes in mice induced a decrease in corneal fluorescein 
staining compared with vehicle.29 At the cellular level, this 
study demonstrated an association with a significant decrease 
in mediators of inflammation, including IL-1α, tumor 
necrosis factor-alpha (TNF-α), and conjunctival TNF-α. 
This led to a decrease in dry eye signs, as well as in inflam-
matory changes in ocular surface disease. This study was a 
critical demonstration of the potential of topically applied 
fatty acids, thus bypassing excess caloric intake and   possible 
gastrointestinal adverse effects often associated with oral 
supplementation.29 This was demonstrated via the   controlled 
adverse environment model to induce dysfunctional tear 
syndrome.
Upon ingestion, omega 3-molecules, ie, eicosapen-
taenoic acid and docosahexaenoic acid, are converted to 
resolvins. Inflammatory molecules, including prostaglandins, 
  leukotrienes, and lipoxins, are all lipid mediators enhanc-
ing inflammation. Resolvins were first isolated in exudates 
formed in the resolution phase of acute inflammation or in 
tissues, such as the brain, in response to an ischemic insult. 
They were then shown to be produced by human cells and 
were identified in human plasma. Following the breakthrough 
of their identification and full structural composition, they 
were produced by full organic chemical synthesis to explore 
their pharmacological properties in various prophylactic and 
therapeutic disease models.30 Experimental evidence to date 
indicates a significant potential for eicosapentaenoic acid-
derived resolvin E1 in managing both acute and chronic 
inflammation, with particularly strong evidence in models 
of colitis, periodontitis, and arthritis, and including pro-
found disease-modifying properties. In other experimental 
conditions, the administration of the docosahexaenoicacid 
analog, NPD1, prevented ischemia-induced brain damage, 
prevented stress-induced apoptosis of retinal epithelial Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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cells, and accelerated the recovery of corneal epithelial 
lesions. The highly specific stereochemistry of resolvin E1 
is required for its biological activity down to picomolar 
  concentrations. Resolvin E1 is eventually deactivated in 
tissues by   oxidation to   18-oxo-RvE1, and is catabolized 
following   omegahydroxylation. This drug protects the ocu-
lar surface and most importantly, promotes healing after 
the insult has passed. Resolvin RX-10045 (Resolvyx®) 
has completed Phase I/II investigation in 232 patients, and 
demonstrated clinically   significant improvement in signs and 
symptoms of dysfunctional tear syndrome, including dryness, 
  stinging, burning, grittiness, and discomfort.31 Symptom 
relief was reported during the first week of treatment, and 
lasted throughout the treatment phase of 28 days. Resolvyx 
will be going forward for Phase III investigation.
Anti-infective agents
Azithromycin 1% (AzaSiteTM) is an antibiotic which has 
demonstrated excellent results in the treatment of   anterior 
and posterior blepharitis.32 Used synergistically with 
other treatments promoting aqueous secretion, it has been 
recognized as a leading medication in combating ocular 
surface disease. It has been shown to change the consistency 
of the meibum, loosening debris which causes the plugging 
of glands critical in the preservation of the healthy tear film.32 
Inspire Pharmaceutical Inc, is currently pursuing Phase III 
clinical investigation of AzaSite in the treatment of posterior 
blepharitis. It is currently approved for the treatment of 
bacterial conjunctivitis.
Autologous serum
In addition to secretagogs and molecules targeting the inflam-
matory cascade, another very important and useful therapy 
in combating ocular surface disease and dysfunctional tear 
syndrome has been the application of autologous serum. Our 
attempts at mimicking the human tear film with synthetic 
lubricants have been useful, yet lack crucial tear film compo-
nents, such as epidermal growth factor, neurotrophic growth 
factor, fibronectin, vitamin A, and lysozymes, all of which 
play an important role in the maintenance of the ocular sur-
face. Autologous serum has been proven to be beneficial in the 
treatment of persistent epithelial defects, superior limbic kera-
toconjunctivitis, dysfunctional tear syndrome, Sjögren’s syn-
drome, and neurotrophic keratopathy.33–36 Autologous serum 
has been available for many years, yet is it not widely used 
due to the formulation process necessitating a compounding 
pharmacy, and frequent blood draws from the patient. Patients 
beginning treatment with autologous serum must be educated 
regarding the level of commitment necessary for the cost of 
autologous serum. We feel it is an advanced treatment which 
is indicated in   difficult cases of ocular surface disease and 
dysfunctional tear syndrome. In addition to reported success 
in these patients, Kojima et al reported statistically significant 
superiority of autologous serum to nonpreserved artificial 
tears in a prospective randomized, case-controlled study look-
ing at 37 eyes of patients suffering from severe dysfunctional 
tear syndrome.37 The autologous serum arm showed superior 
results in film breakup time, sodium fluorescein and Rose 
Bengal staining, and pain symptom scores.33 We consider this 
study to be especially important in evaluating the impact of 
autologous serum because punctal occlusion was not used as 
in previous studies, and all patients underwent a two-week 
washout period prior to treatment.
In addition to topically applied medicines, several 
novel devices have been applied, with promising results in 
diagnosing, as well as treating, ocular surface disease and 
dysfunctional tear syndrome.
Intense pulsed light therapy
Intense pulsed light therapy has been successfully applied 
in the treatment of ocular surface disease by targeting 
meibomian gland dysfunction.38 The impact of meibomian 
gland dysfunction has been increasingly implicated as 
having a significant role in the breakdown of the healthy tear 
complex. Meibum secretion serves to preserve healthy tear 
film. Meibomian gland dysfunction causes the meibum to 
accumulate deep in the gland, resulting in premature tear 
evaporation and accumulation of inflammatory mediators 
onto the ocular surface. Inflammation on the eyelid is 
evident, as seen by the formation of telangiectatic vessels. 
These abnormal vessels are also seen in facial rosacea. 
Telangiectasia formation is the hallmark sign of facial 
rosacea. Patients receiving intense pulsed light treatment 
for facial rosacea reported improved ocular surface disease 
symptoms. This is how early investigation into the use of 
intense pulsed light as a treatment for meibomian gland 
dysfunction was born, and a research grant in 2004 allowed 
Toyos et al to demonstrate the efficacy of intense pulsed light 
in ocular surface disease.38
Intense pulsed light emits energy in the visible spectrum 
between the near and mid-infrared wavelengths. Hemoglobin 
absorbs the energy and coagulates, causing thrombosis of 
the abnormal vessels.39 These closed vessels can no longer 
continue to send proinflammatory mediators to the mebomian 
gland. We have treated many patients with intense pulsed light 
and have seen significantly improved meibomian gland func-Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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tion and lipid secretion in intense pulsed light-treated patients 
who had significant meibomian gland dysfunction. When 
appropriately applied, coupled with topical treatment, intense 
pulsed light has been shown to be very effective. We predict 
that this is a treatment that will be widely used.
Amniotic membrane 
transplantation
The amniotic membrane is the inner most layer of the placenta, 
consisting of a thick basement membrane and a vascular 
stromal matrix.40 It has effectively been used as a temporary 
patch to promote healing of the ocular surface by reducing 
inflammation and scar formation.40 This healing effect lends 
its use in multiple cases of ocular surface pathology, including 
corneal ulcers, severe ocular surface desiccation from chemical 
and thermal burns, limbal stem cell deficiency, and scleral 
melt.41–43 Amniotic membrane transplantation has also been 
successfully used recently in the treatment of Stevens–Johnson 
syndrome and toxic epidermal necrolysis.44 Recent studies and 
applications of amniotic membrane provide confirmation of 
earlier investigations and there is mounting agreement that 
early intervention with amniotic transplantation in cases of 
severe pathology is key to preserving the ocular surface and 
ameliorating visual function.
Conclusion
Ocular surface disease continues to be a common and 
important clinical condition. Even though a number of cur-
rent therapies can improve symptoms and findings in many 
cases, affected people often live with significant symptoms 
and disability due to the condition. Much active investigation 
is being directed towards understanding and treating ocular 
surface disease more effectively.
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